Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program
Bluebird Bio Shares Are Trading Higher After the Company Announced It Joined the CMMI Cell and Gene Therapy Access Model and Will Offer Outcomes-based Agreements to Expand Medicaid Access to LYFGENIA Gene Therapy for Sickle Cell Disease.
CMS Rolls Out New Payment Model for Vertex, Bluebird Gene Therapies
10 Health Care Stocks Whale Activity In Today's Session
S&P and Nasdaq on Track for Third Record Close This Week | Live Stock
Ready Capital Corporation Announces Pricing of Public Offering of Senior Notes Due 2029